Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis

Sudarshawn Damodharan, James Tonsgard · 2026

Read Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis by Sudarshawn Damodharan, James Tonsgard (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0359957.txt.

Description

Sudarshawn Damodharan and James Tonsgard wrote this 2026 PLOS ONE research article. It is a systematic review, combined with a meta-analysis, of MEK inhibitors, a class of targeted drugs. The patients are people with NF1, a genetic condition, who have symptomatic, inoperable plexiform neurofibromas, tumors growing along nerves that surgery cannot safely remove.

The review weighs efficacy and safety together across the available studies. Families facing these disfiguring and painful tumors have few options, so a careful pooling of drug evidence guides real treatment choices. Neurologists and oncologists who manage NF1 are the readers who need this balanced summary.

Catalog record

CREATORSudarshawn Damodharan, James Tonsgard
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49094
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0359957

Browse the full library · About the Tower of Babel